306 related articles for article (PubMed ID: 19842933)
1. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
Meyer S; Schaefer S; Stolk L; Arp P; Uitterlinden AG; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Kann PH
Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
[TBL] [Abstract][Full Text] [Related]
2. Additive effect of GHRd3 and COLIA1 polymorphisms on the GH-substitution dose in GH-deficient adults.
Hartleb S; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Pfützner A; Kann PH; ;
Pharmacogenomics; 2011 Dec; 12(12):1653-61. PubMed ID: 22026923
[TBL] [Abstract][Full Text] [Related]
3. Exon 3-deleted genotype of growth hormone receptor (GHRd3) positively influences IGF-1 increase at generation test in children with idiopathic short stature.
Toyoshima MT; Castroneves LA; Costalonga EF; Mendonca BB; Arnhold IJ; Jorge AA
Clin Endocrinol (Oxf); 2007 Oct; 67(4):500-4. PubMed ID: 17555512
[TBL] [Abstract][Full Text] [Related]
4. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
Binder G; Baur F; Schweizer R; Ranke MB
J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
[TBL] [Abstract][Full Text] [Related]
5. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
6. Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome.
Binder G; Trebar B; Baur F; Schweizer R; Ranke MB
Clin Endocrinol (Oxf); 2008 Apr; 68(4):567-72. PubMed ID: 17973940
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
Jorge AA; Marchisotti FG; Montenegro LR; Carvalho LR; Mendonca BB; Arnhold IJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms.
Meyer S; Schaefer S; Ivan D; Stolk L; Arp P; Uitterlinden AG; Nawroth PP; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Kann PH
Pharmacogenomics; 2009 Feb; 10(2):293-302. PubMed ID: 19207031
[TBL] [Abstract][Full Text] [Related]
9. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study.
Audí L; Carrascosa A; Esteban C; Fernández-Cancio M; Andaluz P; Yeste D; Espadero R; Granada ML; Wollmann H; Fryklund L;
J Clin Endocrinol Metab; 2008 Jul; 93(7):2709-15. PubMed ID: 18445665
[TBL] [Abstract][Full Text] [Related]
10. Association of serum components of the GH-IGFs-IGFBPs system with GHR-exon 3 polymorphism in normal and idiopathic short stature children.
Ballerini MG; Domené HM; Scaglia P; Martínez A; Keselman A; Jasper HG; Ropelato MG
Growth Horm IGF Res; 2013 Dec; 23(6):229-36. PubMed ID: 23999134
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children.
Carrascosa A; Audí L; Esteban C; Fernández-Cancio M; Andaluz P; Gussinyé M; Clemente M; Yeste D; Albisu MA
J Clin Endocrinol Metab; 2008 Jan; 93(1):147-53. PubMed ID: 17925340
[TBL] [Abstract][Full Text] [Related]
12. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age.
Carrascosa A; Audí L; Fernández-Cancio M; Esteban C; Andaluz P; Vilaró E; Clemente M; Yeste D; Albisu MA; Gussinyé M
J Clin Endocrinol Metab; 2008 Mar; 93(3):764-70. PubMed ID: 18160465
[TBL] [Abstract][Full Text] [Related]
13. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency.
Barbosa EJ; Palming J; Glad CA; Filipsson H; Koranyi J; Bengtsson BA; Carlsson LM; Boguszewski CL; Johannsson G
J Clin Endocrinol Metab; 2009 Feb; 94(2):639-44. PubMed ID: 19050057
[TBL] [Abstract][Full Text] [Related]
14. Different relationships between the first 2 years on growth hormone treatment and the d3-growth hormone receptor polymorphism in short small-for-gestational-age (SGA) children.
Dörr HG; Bettendorf M; Hauffa BP; Mehls O; Rohrer T; Stahnke N; Pfäffle R; Ranke MB;
Clin Endocrinol (Oxf); 2011 Nov; 75(5):656-60. PubMed ID: 21623854
[TBL] [Abstract][Full Text] [Related]
15. The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients.
Carrascosa A; Esteban C; Espadero R; Fernández-Cancio M; Andaluz P; Clemente M; Audí L; Wollmann H; Fryklund L; Parodi L;
J Clin Endocrinol Metab; 2006 Sep; 91(9):3281-6. PubMed ID: 16804042
[TBL] [Abstract][Full Text] [Related]
16. The common exon 3 polymorphism of the growth hormone receptor gene and the effect of growth hormone therapy on growth in Korean patients with Turner syndrome.
Ko JM; Kim JM; Cheon CK; Kim DH; Lee DY; Cheong WY; Kim EY; Park MJ; Yoo HW
Clin Endocrinol (Oxf); 2010 Feb; 72(2):196-202. PubMed ID: 19681916
[TBL] [Abstract][Full Text] [Related]
17. The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy.
Adetunji OR; MacFarlane IA; Javadpour M; Alfirevic A; Pirmohamed M; Blair JC
Eur J Endocrinol; 2009 Oct; 161(4):541-6. PubMed ID: 19605543
[TBL] [Abstract][Full Text] [Related]
18. d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype.
Montefusco L; Filopanti M; Ronchi CL; Olgiati L; La-Porta C; Losa M; Epaminonda P; Coletti F; Beck-Peccoz P; Spada A; Lania AG; Arosio M
Clin Endocrinol (Oxf); 2010 May; 72(5):661-7. PubMed ID: 20447065
[TBL] [Abstract][Full Text] [Related]
19. The exon 3 deleted growth hormone receptor gene is associated with small birth size and early pubertal onset in healthy boys.
Sørensen K; Aksglaede L; Petersen JH; Leffers H; Juul A
J Clin Endocrinol Metab; 2010 Jun; 95(6):2819-26. PubMed ID: 20382688
[TBL] [Abstract][Full Text] [Related]
20. Comparison between weight-based and IGF-I-based growth hormone (GH) dosing in the treatment of children with GH deficiency and influence of exon 3 deleted GH receptor variant.
Marchisotti FG; Jorge AA; Montenegro LR; Berger K; de Carvalho LR; Mendonca BB; Arnhold IJ
Growth Horm IGF Res; 2009 Apr; 19(2):179-86. PubMed ID: 19036620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
